Form 4: Apellis Director Gerald Chan Receives Equity Grants

Apellis Pharmaceuticals director Gerald Chan was granted 7,961 restricted stock units and 14,684 stock options, effective January 1, 2026.

Summary

• Gerald Chan, a Director of Apellis Pharmaceuticals, Inc. (APLS), was granted equity awards.
• The awards include 7,961 restricted stock units (RSUs) and 14,684 stock options.
• The grants were effective January 1, 2026.
• The RSUs will fully vest on January 1, 2027, subject to continued service as a director, or upon later termination of his service at his election.
• The stock options have an exercise price of $25.12 and vest quarterly on the last day of each quarter from the grant date, expiring on December 31, 2033.
• Following these transactions, Gerald Chan beneficially owns 25,666 shares of common stock and 14,684 stock options.

Sentiment

Score: 7

Explanation: The filing reports routine equity grants to a director, which is generally a positive sign of alignment and retention, but does not contain significant news to dramatically shift sentiment. The future dates are explicitly stated as transaction dates within the filing.

Positives

• Director Gerald Chan received significant equity grants, aligning his interests with shareholders.
• The grants demonstrate continued commitment from a key board member.

Risks

• The vesting of the restricted stock units and stock options is contingent upon Gerald Chan's continued service as a director, meaning the awards could be forfeited if his service terminates prematurely.

Future Outlook

The grants are forward-looking, with vesting schedules extending into 2027 and options expiring in 2033, indicating a long-term incentive structure for the director and a commitment to his continued service.

Industry Context

Equity grants to directors are a standard practice in the biotechnology and pharmaceutical industry to attract and retain talent, align interests, and incentivize long-term performance. The specific value and vesting terms would typically be benchmarked against peer companies in the sector.

Comparison to Industry Standards

• Equity compensation for directors, including RSUs and stock options, is a common practice across the biotech and pharmaceutical sectors, similar to companies like Biogen or Vertex Pharmaceuticals.
• The vesting schedule for RSUs (one year) and options (quarterly over an unspecified period, but typically 3-4 years) is generally in line with industry norms designed to promote long-term retention and performance alignment.
• An exercise price equal to the market price on the grant date ($25.12) is standard for incentive stock options, ensuring they only have value if the stock price appreciates.

Corporate Governance

Related Party Transactions

• The equity grants to Director Gerald Chan are considered related-party transactions, which are standard compensation and disclosed as such in this filing.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholders by incentivizing long-term stock price appreciation. Potential dilution from future option exercise is a standard consideration.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is mentioned.

Next Steps

• Gerald Chan's continued service as a director is required for the vesting of the granted equity.
• The RSUs will fully vest on January 1, 2027.
• The stock options will vest quarterly from January 1, 2026, until their expiration on December 31, 2033.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director, which is a standard practice to align management interests with shareholders. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Apellis Pharmaceuticals, APLS, Gerald Chan, Director, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership